Shown to be highly effective in strengthening bones and protecting against fractures in all key sites, including hip and spine[1] Once-yearly dosing provides potential for compliance benefits and long ...

ZURICH (Reuters) - Novartis AG's Aclasta was more effective than Procter & Gamble Co's Actonel in increasing bone mass in patients with the bone-thinning disease osteoporosis, a study showed. A ...

Novartis says that Aclasta (zoledronic acid) has won its first approval for the treatment of Paget’s bone disease in all 25 of the European Union member states as well as Norway and Iceland. Novartis ...

Novartis tapped MRM Worldwide, an interactive and relationship marketing company, to undertake European patient communications for its Aclasta CRM program, it was announced yesterday. Aclasta is an ...